Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arvinas Inc
(NQ:
ARVN
)
34.65
+1.39 (+4.18%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
750,667
Open
32.79
Bid (Size)
31.46 (1)
Ask (Size)
38.60 (1)
Prev. Close
33.26
Today's Range
32.79 - 34.86
52wk Range
13.57 - 53.08
Shares Outstanding
68,300,000
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Analyst Ratings For Arvinas
May 17, 2024
Via
Benzinga
Walmart Posts Upbeat Earnings, Joins Canada Goose, Lightspeed Commerce And Other Big Stocks Moving Higher On Thursday
May 16, 2024
Via
Benzinga
Performance
YTD
-16.51%
-16.51%
1 Month
-0.72%
-0.72%
3 Month
-31.52%
-31.52%
6 Month
+59.16%
+59.16%
1 Year
+14.24%
+14.24%
More News
Read More
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
May 16, 2024
From
Arvinas Inc.
Via
GlobeNewswire
NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday
May 15, 2024
Via
Benzinga
Navigating 7 Analyst Ratings For Arvinas
February 28, 2024
Via
Benzinga
Arvinas: Q4 Earnings Insights
February 27, 2024
Via
Benzinga
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
May 09, 2024
From
Arvinas Inc.
Via
GlobeNewswire
ARVN Stock Earnings: Arvinas Beats EPS, Misses Revenue for Q1 2024
May 07, 2024
Via
InvestorPlace
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 07, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Present at Upcoming Investor Conferences
May 02, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Inc. (NASDAQ: ARVN) Climbs to New 52-Week High
February 06, 2024
Via
Investor Brand Network
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
April 24, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
April 11, 2024
Via
Investor's Business Daily
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
April 11, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
March 18, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
March 04, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
March 01, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
March 01, 2024
Via
Benzinga
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
February 27, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Announces Chief Financial Officer Transition
February 20, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
February 20, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
February 14, 2024
From
CARRICK THERAPEUTICS LIMITED
Via
GlobeNewswire
SPS Commerce Posts Upbeat Results, Joins Masonite International, Impinj And Other Big Stocks Moving Higher On Friday
February 09, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
February 06, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
February 01, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.